Rubicon Research LimitedPharmaceuticals & HealthcareRUBICON
Q1 FY26 concall · earnings callRubicon Research Limited
Rubicon delivered strong top-line and bottom-line growth, raised EBITDA guidance, and advanced its strategic manufacturing footprint with a new U.S. site.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue | ₹534.3 Cr | 52% | |
| EBITDA | ₹129.1 Cr | 63.2% | |
| PAT | ₹84.8 Cr | 96% | |
| Gross Margin | 67.7% | 140 bps | |
| R&D as % of Revenue | 10.9% | — | |
| ROCE | 36% | — | |
| USD Revenue | USD55 million | 32% |
TL;DR
- Revenue grew 51% YoY and EBITDA 65% YoY, with PAT up over 95%.
- Raised full-year EBITDA margin guidance to 23% from 22-23%, despite cost headwinds.
- Acquired a manufacturing site in New Jersey, USA, and received FDA approval for the Pithampur site.
- Gross margin improved sequentially by 140 bps to 67.7%.
- R&D productivity is high at a 5.5x multiple, and commercialization rate remains strong at 88%.
- Net working capital improved to 114 days but is expected to normalize to 125-130 days.
Said on the call
“We are slightly up guiding for around now earlier our guidance was 22% to 23% on EBITDA but now we are comfortable to revise this upwards for the whole of FY27 to 23%.”
From the Q&A
| Topic | What management said |
|---|---|
| Product Concentration & Pipeline | Management stated growth is broad-based and the portfolio concentration has been range-bound; they do not comment on specific product pipeline details due to commercial sensitivity. |
| US Manufacturing Facility & Margins | The New Jersey acquisition is strategic for government business and supply chain diversification; it is not expected to dilute margins and could be margin accretive. |
| Specialty Portfolio Disclosure | The company shares only the share of gross profit from specialty (36% in Q1) and the number of specialty products annually, but will not expand disclosures further. |
| Capacity at Pithampur | The site has significant room for expansion, using only 5-6 acres of a ~30-acre site, with enough capacity for near-term ramp-up and long-term growth. |
| Arinna Acquisition Impact | Arinna contributed ~INR12 crores to revenue with no material EBITDA impact in Q1; the focus for the year is on fixing growth levers, not profitability. |
| R&D Strategy | R&D spending will follow a portfolio-based approach across various product types, not concentrated on a few big bets. |
Guidance
- Full-year FY27 EBITDA margin guidance revised upwards to 23%.
- Net working capital expected to be in the range of 125 to 130 days.
- R&D spend guidance of INR500 crores over nine quarters (FY26, FY27, Q1 FY28) is on track.
- R&D spend as a percentage of revenue will continue at 10% to 11%.
- Commercial ramp-up at Pithampur facility expected from Q1 calendar year 2027.
- Commercialization at New Jersey site expected in calendar year 2027.
Source
Summary written from the transcript filed by Rubicon Research Limited for the call held on 14 Aug 2026; published 19 Aug 2026, 13:21 IST.
More Q1 FY26 concalls ·How verification works ·Report an error